Pacira BioSciences (PCRX) Capital Expenditures Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -21.54% |
| 10 | Pacira BioSciences | 1.08 Bn | 876.91 Mn | 140.96 Mn | 77.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.57% |
| Dec 31, 2025 | 107.38% |
| Sep 30, 2025 | -5.43% |
| Jun 30, 2025 | 174.37% |
| Mar 31, 2025 | 26.36% |
| Dec 31, 2024 | -121.57% |
| Sep 30, 2024 | 545.75% |
| Jun 30, 2024 | 2,708.09% |
| Mar 31, 2024 | -73.05% |
| Dec 31, 2023 | 149.29% |
| Sep 30, 2023 | -117.72% |
| Jun 30, 2023 | -98.97% |
| Mar 31, 2023 | -63.93% |
| Dec 31, 2022 | 160.41% |
| Sep 30, 2022 | 127.41% |
| Jun 30, 2022 | 24.72% |
| Mar 31, 2022 | -52.24% |
| Dec 31, 2021 | -85.36% |
| Sep 30, 2021 | -343.53% |
| Jun 30, 2021 | -19.06% |